Cambridge, United Kingdom

Cassandra Van Krinks

USPTO Granted Patents = 8 

Average Co-Inventor Count = 9.5

ph-index = 4

Forward Citations = 155(Granted Patents)


Company Filing History:


Years Active: 2017-2025

Loading Chart...
8 patents (USPTO):Explore Patents

Title: The Innovative Contributions of Cassandra Van Krinks

Introduction

Cassandra Van Krinks, a prominent inventor based in Cambridge, GB, has made significant strides in the field of biomedicine. Holding an impressive seven patents, she is noted for her contributions to antibody research, particularly in developing innovative therapies targeting cancer treatments.

Latest Patents

Among her latest patents is a groundbreaking invention related to anti-PD-L1 antibodies. This invention explores the potential of bispecific antibodies that contain a domain specifically targeting PD-L1. Furthermore, her work on immunocytokines, which fuse anti-PD-L1 antibodies to cytokines such as IL-2, has opened new avenues for treatment methods. These inventions not only have significant implications for therapeutic uses but also involve pharmaceutical compositions comprising her patented antibodies and immunocytokines.

Career Highlights

Cassandra is currently affiliated with Kymab Limited, where her expertise in biotechnology and antibody development plays a crucial role in the company's mission. Her deep understanding and innovative approach to antibody engineering have positioned her as a key figure in her organization, helping to drive forward pioneering research in the sector.

Collaborations

Throughout her career, Cassandra has collaborated with noted professionals in her field, including Jamie Iain Campbell and Stephen D Gillies. These partnerships reflect her commitment to advancing scientific knowledge and her ability to work effectively within teams to push the boundaries of current therapies.

Conclusion

Cassandra Van Krinks stands out as an exemplary inventor in the biomedical field. Her impressive portfolio of seven patents demonstrates her dedication to innovation, especially in developing new treatment modalities for serious health conditions. Her ongoing work at Kymab Limited, combined with fruitful collaborations, truly underscores her impact on the landscape of medical research and pharmaceuticals.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…